Glen C. MacDonald
Chief Executive Officer bij Leucadia Finance Partners, Inc.
Vermogen: 45 277 $ op 31-03-2024
Profiel
Glen C.
MacDonald is currently the President, CEO, CFO & Director at Leucadia Finance Partners, Inc. He was previously the Chief Scientific Officer at Viventia Biotech, Inc. from 2005 to 2012 and again from 2012 to 2016.
He was also the Chief Scientific Officer at Sesen Bio, Inc. from 2016 to 2017.
Additionally, he held a position as Principal at Princess Margaret Hospital Foundation and The University of North Carolina at Charlotte.
Dr. MacDonald received his undergraduate degree from the University of Guelph in 1980, his graduate degree from the University of Manitoba in 1987, and his doctorate from the University of Manitoba in 1993.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 02-03-2023 | 19 946 ( 0.05% ) | 45 277 $ | 31-03-2024 |
Actieve functies van Glen C. MacDonald
| Bedrijven | Functie | Begin |
|---|---|---|
Leucadia Finance Partners, Inc.
 Leucadia Finance Partners, Inc. Financial ConglomeratesFinance Leucadia Finance Partners, Inc. provides investment services. The company was founded on January 12, 2014 and is headquartered in Vancouver, Canada. | Chief Executive Officer | - |
Eerdere bekende functies van Glen C. MacDonald
| Bedrijven | Functie | Einde |
|---|---|---|
Viventia Bio, Inc.
 Viventia Bio, Inc. BiotechnologyHealth Technology Viventia Bio, Inc. operates as a biologics oncology company, which focuses on designing, engineering, and developing targeted protein therapeutics. The company was founded by Leslie Lewis Dan in October 2012 and is headquartered in Winnipeg, Canada. | Chief Tech/Sci/R&D Officer | 01-09-2016 |
Viventia Biotech, Inc.
 Viventia Biotech, Inc. BiotechnologyHealth Technology Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada | Chief Tech/Sci/R&D Officer | 01-01-2012 |
| CARISMA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
| Princess Margaret Hospital Foundation | Corporate Officer/Principal | - |
| The University of North Carolina at Charlotte | Corporate Officer/Principal | - |
Opleiding van Glen C. MacDonald
| University of Guelph | Undergraduate Degree |
| University of Manitoba | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
Viventia Biotech, Inc.
Viventia Biotech, Inc. BiotechnologyHealth Technology Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada | Health Technology |
Leucadia Finance Partners, Inc.
Leucadia Finance Partners, Inc. Financial ConglomeratesFinance Leucadia Finance Partners, Inc. provides investment services. The company was founded on January 12, 2014 and is headquartered in Vancouver, Canada. | Finance |
| Princess Margaret Hospital Foundation | |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Viventia Bio, Inc.
Viventia Bio, Inc. BiotechnologyHealth Technology Viventia Bio, Inc. operates as a biologics oncology company, which focuses on designing, engineering, and developing targeted protein therapeutics. The company was founded by Leslie Lewis Dan in October 2012 and is headquartered in Winnipeg, Canada. | Health Technology |
